Roche Holding AG Bearer Shares RHHBF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if RHHBF is a good fit for your portfolio.
News
-
Roche prepares for business after boom from COVID-related products
-
Roche's Lung-Cancer Drug Alecensa Gets New FDA Approval
-
Roche's Genentech Gets FDA Approval for Lung-Cancer Treatment
-
Roche's Columvi Meets Main Goal in Lymphoma Phase 3 Trial
-
Roche, Eli Lilly Alzheimer's Blood Test to Get Expedited FDA Review
-
Roche Gets FDA Approval for Malaria Screen Test
-
Lonza Shares Jump on U.S. Manufacturing Facility Buy From Roche
-
Lonza to Buy U.S. Manufacturing Facility From Roche For $1.2 Billion
Trading Information
- Previous Close Price
- $254.76
- Day Range
- $259.00–259.00
- 52-Week Range
- $243.42–354.00
- Bid/Ask
- $252.33 / $288.00
- Market Cap
- $206.49 Bil
- Volume/Avg
- 11 / 189
Key Statistics
- Price/Earnings (Normalized)
- 11.89
- Price/Sales
- 3.10
- Dividend Yield (Trailing)
- 4.19%
- Dividend Yield (Forward)
- 4.75%
- Total Yield
- 4.19%
Company Profile
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stock Style Box
- Large Value
- Total Number of Employees
- 103,605
- Website
- https://www.roche.com
Competitors
Valuation
|
Metric
|
RHHBF
|
MRK
|
ABBV
|
|---|---|---|---|
Price/Earnings (Normalized) | 11.89 | 58.76 | 14.94 |
Price/Book Value | 5.92 | 8.00 | 36.12 |
Price/Sales | 3.10 | 5.29 | 5.34 |
Price/Cash Flow | 11.39 | 18.59 | 15.44 |
Price/Earnings
RHHBF
MRK
ABBV
Financial Strength
|
Metric
|
RHHBF
|
MRK
|
ABBV
|
|---|---|---|---|
Quick Ratio | 0.99 | 0.68 | 0.72 |
Current Ratio | 1.35 | 1.25 | 0.94 |
Interest Coverage | 14.93 | 3.97 | 3.95 |
Quick Ratio
RHHBF
MRK
ABBV
Profitability
|
Metric
|
RHHBF
|
MRK
|
ABBV
|
|---|---|---|---|
Return on Assets (Normalized) | 17.03% | 5.22% | 14.14% |
Return on Equity (Normalized) | 53.42% | 13.56% | 172.29% |
Return on Invested Capital (Normalized) | 26.30% | 8.29% | 27.87% |
Return on Assets
RHHBF
MRK
ABBV
Drug Manufacturers - General Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
LLY
| Eli Lilly and Co | Yjybsfhnlg | Zxbhq | $698.5 Bil | |
JNJ
| Johnson & Johnson | Bdlnylc | Fjrx | $359.2 Bil | |
MRK
| Merck & Co Inc | Rwcpflqwg | Fgm | $323.0 Bil | |
ABBV
| AbbVie Inc | Wylkmpjg | Ldyrv | $289.2 Bil | |
AZN
| AstraZeneca PLC ADR | Frxrgtxtjd | Ltsw | $236.3 Bil | |
NVS
| Novartis AG ADR | Qbkfpqr | Pblm | $197.3 Bil | |
RHHBY
| Roche Holding AG ADR | Vmwlnkkpn | Vvtxn | $192.5 Bil | |
AMGN
| Amgen Inc | Ytxbcfvqr | Pkbdy | $167.0 Bil | |
PFE
| Pfizer Inc | Sgdwncyy | Xrsh | $157.5 Bil | |
SNY
| Sanofi SA ADR | Rqtpghjd | Ygvv | $122.3 Bil |